🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "significant breakthrough" in the battle against increasingly resistant strains of the bacteria, according to scientists.

A Global Challenge

Cases of gonorrhoea are increasing globally, with estimates suggesting more than 82 million new cases annually. Particularly high rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely step in the face of growing infection rates, increasing antimicrobial resistance and the highly restricted treatment choices currently available.”

Health officials are particularly alarmed about the surge in treatment-resistant strains. The WHO has designated it as a "critical concern". Ongoing monitoring revealed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Drugs Receive Clearance

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in December for use against gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Experts anticipate that focused deployment of this new drug will help hinder the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, also received approval in concurrent days. This treatment, which is also used to treat urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Partnership

This new treatment emerged from a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to see it through.

“This approval signifies a huge turning point in the therapy of superbug gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Testing Outcomes and Worldwide Availability

Based on findings published in a prominent scientific publication, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the typical regimen, which involves a dual-drug approach. The research included hundreds of participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the ability to make available and distribute the drug in a wide range of regions with limited resources.

Clinicians treating patients have voiced optimism. Having a easy-to-administer therapy such as this is seen as a "revolutionary step" for gonorrhoea control. This is viewed as crucial to lessen the impact of the infection for patients and to stop the proliferation of highly drug-resistant gonorrhoea around the world.